Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.67 |
| ▸ | CNR1 | P21554 | 2/20 | 0.67 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 2/20 | 0.53 |
| ▸ | FABP1 | P07148 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.50 |
| ▸ | ACSL6 | Q9UKU0 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081340 | 1.00 | CNR2 (0.67) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL4076679 | 1.00 | CNR2 (0.67) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL4110127 | 1.00 | CNR2 (0.67) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL4114764 | 1.00 | CNR2 (0.67) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL2158881 | 1.00 | CNR2 (0.67) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL3937528 | 0.98 | CNR2 (0.64) | CNR2CNR1ALBCYSLTR2CYSLTR1 | |
| SCHEMBL3947131 | 0.93 | CNR2 (0.58) | CNR2CNR1CYSLTR2CYSLTR1CHRNB2 | |
| Hexanoate SCHEMBL28988124 | 0.93 | CNR2 (0.60) | CNR2CNR1CYSLTR2CYSLTR1 | |
| SCHEMBL30639265 | 0.90 | PPARA (0.58) | ALBCYSLTR2CYSLTR1PPARAFABP1 | |
| Azelaic Acid SCHEMBL28605694 | 0.89 | FFAR1 (0.63) | CNR2CNR1CYSLTR2CYSLTR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7527809-B2 | Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof | CANON KABUSHIKI KAISHA (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060263432-A1 | Useful as a sustained release pharmaceutical preparation; microcapsule stably containing a drug, especially a water-soluble drug at high content and which has magnetic property; drug delivery; excellent in dispersibility and magnetic response | CANON KABUSHIKI KAISHA (JP) | 2006-11-23 | — | — | US | disclosed |
| WO-2004096188-A1 | POLYHYDROXYALKANOATE-CONTAINING MAGNETIC STRUCTURE, AND MANUFACTURING METHOD AND USE THEREOF | CANON KABUSHIKI KAISHA (JP) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060263432-A1 | Useful as a sustained release pharmaceutical preparation; microcapsule stably containing a drug, especially a water-soluble drug at high content and which has magnetic property; drug delivery; excellent in dispersibility and magnetic response | SKP1, HAMP, AUP1 | CNR2 1838/4885CNR1 1382/4885ALB 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.